Home | Welcome to Contract Pharma   
Last Updated Friday, October 31 2014
Print

Financial Report: BMS



By Kristin Brooks



Published January 24, 2014
Related Searches: Biopharma
BMS

4Q Revenues: $4.4 billion (+6%)

4Q Earnings: $735.0 million (-20%)

YTD Revenues: $16.4 billion (-7%)

YTD Earnings: $2.6 billion (+3%)

Comments: U.S. revenues increased 1% to $2.3 billion in the quarter and international revenues increased 11% to $2.2 billion. Yervoy sales grew 23% to $260 million. Onglyza/Kombiglyze sales were $224 million, up 13%. Sprycel sales grew 30% to $365 million, and Orencia sales were up 22% to $397 million. Abilify sales were down 22% to $635 million, due to loss of patent exclusivity. R&D expenses were down 12% to $957 million. In the quarter, the company announced the sale of its diabetes business as part of an effort to evolve its BioPharma strategy to a specialty care model.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On